Pulse Explorar nav.journalClub Debates Tendencias Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

July 3, 2024

Ver artículo completo

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Recurrent cervical cancer is a life-threatening disease, with limited treatment options available when disease progression occurs after first-line combination therapy.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer | Synapse

Cite This Study

Vergote et al. (Wed,) studied this question.

synapsesocial.com/papers/68e616d2b6db6435875a9dab https://doi.org/https://doi.org/10.1056/nejmoa2313811